ArticleScientific reports2026
Angiotensin II-stimulating versus inhibiting antihypertensives and risk of dementia: a nested case-control study using Australian general practice data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Midlife hypertension is a modifiable risk factor for dementia. The effects of angiotensin II (Ang-II) stimulating versus inhibiting antihypertensive medications (AHMs) on the risk of developing dementia remain unclear. This nested case-control study compared the association between treatment with Ang-II stimulating versus inhibiting AHMs and dementia risk using an Australian general practice dataset, MedicineInsight among 25,134 matched participants. We included 25,134 participants aged ≥ 45 years (6303 cases and 18,831 matched controls) with hypertension and at least one year of AHM therapy between January 1, 2011, and December 31, 2020. Exposure was classified using the proportion of days covered into high (≥ 80%) and lower (< 80%) categories. Participants with high AHM exposure were further classified based on dominant AHM type. Conditional logistic regression was used to assess associations. Using Ang-II stimulating AHMs was associated with a significantly lower risk of development of dementia (adjusted odds ratio: 0.82, 95% CI 0.75-0.89, p < 0.001) compared to using Ang-II inhibiting AHMs. Subgroup analyses revealed a significantly stronger association in males (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.